Bio-Rad Laboratories has unveiled four new Droplet Digital PCR (ddPCR) platforms, expanding its comprehensive product line for life science research and clinical diagnostics.
The launch includes the QX Continuum ddPCR system and the QX700 series, acquired through Bio-Rad’s recent acquisition of Stilla Technologies, a digital PCR developer.
The newly expanded portfolio, which now includes over 400,000 assays, enhances Bio-Rad’s existing QX200 and QX600 ddPCR systems.
The products offer advanced multiplexing, high precision, and absolute quantification, alongside streamlined workflows for research and diagnostic applications.
The QX Continuum ddPCR system targets translational research applications.
It provides a qPCR-like workflow with four-colour multiplexing and up to eight discrete thermal profiles per plate, offering simplicity and flexibility in an all-in-one configuration.
The QX700 series introduces three ddPCR instruments aimed at academic research, environmental testing, cell and gene therapy, and biopharma quality control.
The systems support seven-colour multiplexing and can process over 700 samples per day, featuring continuous loading and user-friendly software for easy data interpretation.
Bio-Rad’s Life Science Group EVP and president Jim Barry said: “With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions.
“The newly introduced platforms complement Bio-Rad’s existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications, including oncology, infectious disease, and genetic research.”
Based in Hercules, California, Bio-Rad Laboratories specialises in life science research and clinical diagnostics.
The company operates worldwide with around 7,700 employees and reported $2.6bn in revenues in 2024.
Its clientele includes universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety, and environmental quality laboratories.
